Although all four biomarkers are available as supplementary data to our previous publication (28), we were disappointed to see that subsequent FSHD transcriptomic studies [e.g. (31,32)] chose to employ only unvalidated subsets of the patented DUX4 target gene biomarker described by Yao et al. (2014) (30), and even then, used different subsets between publications. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.